These results suggest that with the progression of AD, the increase in IL-17A levels in the brain leads to the decreased phagocytic ability of microglia, weakening of Aβ plaque clearance ability, and exacerbation of Aβ plaque deposition and disease progression. Here, IL17A is linked to Alzheimer disease.